Patents Assigned to Meshaberase, LLC
  • Publication number: 20210290569
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Applicants: MESHABERASE, LLC, United States Department of Health and Human Services, National Institutes of Health
    Inventors: Benjamin Rubin, Mark Gilbert, Jinkyu Jung
  • Patent number: 11052057
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 6, 2021
    Assignees: MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Dept of Health and Human Services
    Inventors: Benjamin Rubin, Raj Puri, Bharat Joshi
  • Publication number: 20210196652
    Abstract: Methods for treating or inhibiting dysfunctional tear syndrome (DTS) or symptoms associated therewith, and compositions for use in the methods.
    Type: Application
    Filed: December 11, 2020
    Publication date: July 1, 2021
    Applicant: MESHABERASE, LLC
    Inventor: Benjamin RUBIN
  • Publication number: 20200147010
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: October 7, 2019
    Publication date: May 14, 2020
    Applicants: MESHABERASE, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Benjamin RUBIN, Raj PURI, Bharat JOSHI
  • Publication number: 20190142769
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Applicants: MESHABERASE, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Benjamin RUBIN, Raj PURI, Bharat JOSHI
  • Publication number: 20180042870
    Abstract: The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: September 8, 2017
    Publication date: February 15, 2018
    Applicant: Meshaberase, LLC
    Inventors: Benjamin RUBIN, Raj PURI, Bharat JOSHI